RANKL Inhibition in Fibrous Dysplasia of Bone: A Preclinical Study in a Mouse Model of the Human Disease.

Animals Biomechanical Phenomena Bone and Bones / diagnostic imaging Calcification, Physiologic Denosumab / pharmacology Disease Models, Animal Disease Progression Fibrous Dysplasia of Bone / complications GTP-Binding Protein alpha Subunits, Gs / genetics Humans Mice, Transgenic Osteolysis / blood Peptide Elongation Factor 1 / metabolism Phenotype RANK Ligand / antagonists & inhibitors Rats
BONE REMODELLING DENOSUMAB FIBROUS DYSPLASIA GSα RANKL

Journal

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
ISSN: 1523-4681
Titre abrégé: J Bone Miner Res
Pays: United States
ID NLM: 8610640

Informations de publication

Date de publication:
12 2019
Historique:
received: 08 02 2019
revised: 13 06 2019
accepted: 30 06 2019
pubmed: 12 7 2019
medline: 12 9 2020
entrez: 12 7 2019
Statut: ppublish

Résumé

Fibrous dysplasia of bone/McCune-Albright syndrome (Polyostotic FD/MAS; OMIM#174800) is a crippling skeletal disease caused by gain-of-function mutations of G

Identifiants

DOI: 10.1002/jbmr.3828 PMID: 31295366 PMC: PMC8408916
pubmed: 31295366
doi: 10.1002/jbmr.3828
pmc: PMC8408916
mid: NIHMS1734622
doi:

Substances chimiques

Peptide Elongation Factor 1 0
RANK Ligand 0
Denosumab 4EQZ6YO2HI
GTP-Binding Protein alpha Subunits, Gs EC 3.6.5.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2171-2182

Subventions

Organisme : Intramural NIH HHS
ID : ZIA DE000380
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2019 American Society for Bone and Mineral Research.

Références

N Engl J Med. 2006 Feb 23;354(8):821-31
pubmed: 16495394
J Bone Miner Res. 2010 May;25(5):1103-16
pubmed: 19874199
Bone. 2007 May;40(5):1308-19
pubmed: 17337263
JBMR Plus. 2019 Jan 15;3(8):e10134
pubmed: 31485549
Nat Med. 2011 Oct 23;17(11):1473-80
pubmed: 22019888
N Engl J Med. 1991 Dec 12;325(24):1688-95
pubmed: 1944469
Proc Natl Acad Sci U S A. 2018 Jan 16;115(3):E428-E437
pubmed: 29282319
J Cell Biol. 2004 Dec 20;167(6):1113-22
pubmed: 15611335
J Clin Endocrinol Metab. 2014 Nov;99(11):4133-40
pubmed: 25033066
Rheumatology (Oxford). 2015 Sep;54(9):1747-9
pubmed: 26070936
J Bone Miner Res. 2019 Apr;34(4):653-660
pubmed: 30645769
J Clin Endocrinol Metab. 2003 Oct;88(10):4569-75
pubmed: 14557424
Trends Endocrinol Metab. 2017 Oct;28(10):695-704
pubmed: 28733136
J Bone Miner Res. 1999 Jul;14(7):1104-14
pubmed: 10404010
Nature. 2003 May 15;423(6937):337-42
pubmed: 12748652
Clin Cancer Res. 2012 Aug 15;18(16):4415-24
pubmed: 22711702
Joint Bone Spine. 2014 Dec;81(6):549-50
pubmed: 24962974
Clin Cases Miner Bone Metab. 2016 Sep-Dec;13(3):253-256
pubmed: 28228794
J Bone Miner Res. 2019 Feb;34(2):290-294
pubmed: 30496606
Am J Pathol. 1997 Dec;151(6):1587-600
pubmed: 9403710
Skeletal Radiol. 2017 Oct;46(10):1435-1439
pubmed: 28660402
J Clin Invest. 1996 Jul 1;98(1):30-5
pubmed: 8690800
J Bone Miner Res. 2000 Jan;15(1):120-8
pubmed: 10646121
Trends Mol Med. 2006 Jan;12(1):17-25
pubmed: 16356770
Life Sci. 2016 May 1;152:244-8
pubmed: 26596563
N Engl J Med. 2009 Aug 20;361(8):756-65
pubmed: 19671655
Osteoporos Int. 2014 Feb;25(2):777-82
pubmed: 24311113
Proc Natl Acad Sci U S A. 1992 Jun 1;89(11):5152-6
pubmed: 1594625
Proc Natl Acad Sci U S A. 2018 Jan 16;115(3):E418-E427
pubmed: 29158412
J Bone Miner Res. 2015 Jul;30(7):1280-9
pubmed: 25684625
Clin Cancer Res. 2006 Feb 15;12(4):1221-8
pubmed: 16489077
J Clin Oncol. 2011 Mar 20;29(9):1125-32
pubmed: 21343556
J Basic Clin Pharm. 2016 Mar;7(2):27-31
pubmed: 27057123
PLoS One. 2016 May 10;11(5):e0154680
pubmed: 27163152
Bone. 2003 Sep;33(3):434-42
pubmed: 13678786
Nature. 2018 Sep;561(7722):195-200
pubmed: 30185903
J Bone Miner Res. 2012 Jul;27(7):1462-70
pubmed: 22431375
J Bone Miner Res. 2014 Nov;29(11):2357-68
pubmed: 24764158
Biochem Biophys Res Commun. 2006 Aug 18;347(1):124-32
pubmed: 16815304
J Bone Miner Res. 2006 Dec;21 Suppl 2:P125-31
pubmed: 17229001
Am J Pathol. 2009 Jun;174(6):2160-71
pubmed: 19389927
J Bone Miner Res. 2003 Jul;18(7):1235-46
pubmed: 12854833
J Clin Endocrinol Metab. 2013 Nov;98(11):4483-92
pubmed: 23979955
J Pathol. 1999 Jan;187(2):249-58
pubmed: 10365102
J Pediatr Orthop B. 2003 May;12(3):155-77
pubmed: 12703030
J Bone Miner Res. 2017 Feb;32(2):264-276
pubmed: 27649526

Auteurs

Biagio Palmisano (B)

Department of Molecular Medicine, Sapienza University, Rome, Italy.

Emanuela Spica (E)

Department of Molecular Medicine, Sapienza University, Rome, Italy.

Cristina Remoli (C)

Department of Molecular Medicine, Sapienza University, Rome, Italy.

Rossella Labella (R)

Department of Molecular Medicine, Sapienza University, Rome, Italy.

Annamaria Di Filippo (A)

Department of Molecular Medicine, Sapienza University, Rome, Italy.

Samantha Donsante (S)

Department of Molecular Medicine, Sapienza University, Rome, Italy.

Fabiano Bini (F)

Department of Mechanical and Aerospace Engineering, Sapienza University, Rome, Italy.

Domenico Raimondo (D)

Department of Molecular Medicine, Sapienza University, Rome, Italy.

Franco Marinozzi (F)

Department of Mechanical and Aerospace Engineering, Sapienza University, Rome, Italy.

Alan Boyde (A)

Dental Physical Sciences, Barts' and The London School of Medicine and Dentistry, Queen Mary University of London (QMUL), London, UK.

Pamela Robey (P)

Skeletal Biology Section, National Institute of Dental and Craniofacial Research (NIDCR), National Institutes of Health (NIH), Bethesda, MD, USA.

Alessandro Corsi (A)

Department of Molecular Medicine, Sapienza University, Rome, Italy.

Mara Riminucci (M)

Department of Molecular Medicine, Sapienza University, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › RANKL Inhibition in Fibrous Dysplasia of Bone:...
questionsmedicales.fr › Phénomènes physiques › Phénomènes mécaniques › Phénomènes biomécaniques › RANKL Inhibition in Fibrous Dysplasia of Bone:...
questionsmedicales.fr › Tissus › Tissu conjonctif › Os et tissu osseux › RANKL Inhibition in Fibrous Dysplasia of Bone:...
questionsmedicales.fr › Phénomènes physiologiques de l'appareil locomoteur et du système nerveux › Phénomènes physiologiques du système locomoteur › Développement locomoteur › Biominéralisation › Développement osseux › Calcification physiologique › RANKL Inhibition in Fibrous Dysplasia of Bone:...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › Dénosumab › RANKL Inhibition in Fibrous Dysplasia of Bone:...
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles animaux de maladie humaine › RANKL Inhibition in Fibrous Dysplasia of Bone:...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Évolution de la maladie › RANKL Inhibition in Fibrous Dysplasia of Bone:...
questionsmedicales.fr › Maladies ostéomusculaires › Maladies osseuses › Dysplasies osseuses › Dysplasie fibreuse des os › RANKL Inhibition in Fibrous Dysplasia of Bone:...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Protéines G hétérotrimériques › Sous-unités alpha des protéines G › Sous-unités alpha Gs des protéines G › RANKL Inhibition in Fibrous Dysplasia of Bone:...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › RANKL Inhibition in Fibrous Dysplasia of Bone:...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Souris transgéniques › RANKL Inhibition in Fibrous Dysplasia of Bone:...
questionsmedicales.fr › Phénomènes physiologiques de l'appareil locomoteur et du système nerveux › Phénomènes physiologiques du système locomoteur › Résorption osseuse › Ostéolyse › RANKL Inhibition in Fibrous Dysplasia of Bone:...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines ribosomiques › Facteurs élongation chaîne peptidique › Facteurs d'élongation liés à la GTP phosphohydrolase › Facteur-1 d'élongation de la chaîne peptidique › RANKL Inhibition in Fibrous Dysplasia of Bone:...
questionsmedicales.fr › Phénomènes génétiques › Phénotype › RANKL Inhibition in Fibrous Dysplasia of Bone:...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Facteurs de nécrose tumorale › Ligand de RANK › RANKL Inhibition in Fibrous Dysplasia of Bone:...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Rats › RANKL Inhibition in Fibrous Dysplasia of Bone:...